Content deleted Content added
Activating IUPHAR link. Report errors and suggestions to User_talk:BogBot |
m Bot: Deprecating Template:Cite pmid and some minor fixations |
||
Line 41:
'''3-((2-Methyl-4-thiazolyl)ethynyl)pyridine''' ('''MTEP''') is a research drug that was developed by [[Merck & Co.]] as a selective [[allosteric]] [[Antagonist (pharmacology)|antagonist]] of the [[metabotropic glutamate receptor]] subtype [[Metabotropic glutamate receptor 5|mGluR5]]. Identified through [[structure-activity relationship]] studies on an older mGluR5 antagonist [[2-Methyl-6-(phenylethynyl)pyridine|MPEP]],<ref>{{cite journal |author=Cosford ND, Tehrani L, Roppe J, ''et al.'' |title=3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity |journal=J. Med. Chem. |volume=46 |issue=2 |pages=204–6 |date=January 2003 |pmid=12519057 |doi=10.1021/jm025570j |url=}}</ref> MTEP has subsequently itself acted as a [[lead compound]] for newer and even more improved drugs.<ref>{{cite journal |author=Iso Y, Grajkowska E, Wroblewski JT, ''et al.'' |title=Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications |journal=J. Med. Chem. |volume=49 |issue=3 |pages=1080–100 |date=February 2006 |pmid=16451073 |doi=10.1021/jm050570f |url=}}</ref><ref>{{cite journal |author=Kulkarni SS, Newman AH |title=Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists |journal=Bioorg. Med. Chem. Lett. |volume=17 |issue=11 |pages=2987–91 |date=June 2007 |pmid=17446071 |pmc=1973162 |doi=10.1016/j.bmcl.2007.03.066 |url=}}</ref>
MTEP is both more [[Potency (pharmacology)|potent]] and more [[Functional selectivity|selective]] than MPEP as a mGluR5 antagonist,<ref>{{cite DOI|10.1111/j.1527-3458.2006.00149.x}}</ref> and produces similar [[neuroprotective]],<ref>{{cite DOI|10.1038/sj.bjp.0706219}}</ref><ref>{{
| last1 = Domin | first1 = H.
| last2 = Kajta | first2 = M.
| last3 = Smiałowska | first3 = M.
| title = Neuroprotective effects of MTEP, a selective mGluR5 antagonists and neuropeptide Y on the kainate-induced toxicity in primary neuronal cultures
| journal = Pharmacological reports : PR
| volume = 58
| issue = 6
| pages = 846–858
| year = 2006
| pmid = 17220542
}}</ref><ref>{{cite DOI|10.1016/j.ejphar.2006.09.061}}</ref> [[antidepressant]],<ref>{{cite DOI|10.1016/j.pbb.2005.06.015}}</ref><ref>{{cite DOI|10.1016/j.pnpbp.2006.04.022}}</ref><ref>{{cite DOI|10.1124/jpet.106.103143}}</ref><ref>{{cite DOI|10.1016/j.euroneuro.2006.03.002}}</ref> [[analgesic]],<ref>{{cite DOI|10.1016/j.ejphar.2004.11.005}}</ref><ref>{{cite DOI|10.1007/s00213-005-2143-4}}</ref> and [[anxiolytic]] effects but with either similar or higher [[efficacy]] depending on the test used.<ref>{{cite DOI|10.1016/j.neuropharm.2004.04.013}}</ref><ref>{{cite DOI|10.1038/sj.npp.1300540}}</ref><ref>{{cite DOI|10.1016/j.ejphar.2005.03.028 |url=}}</ref><ref>{{cite DOI|10.1016/j.neuropharm.2007.08.002}}</ref>
MTEP also has similar efficacy to MPEP in reducing the symptoms of [[morphine]] [[Drug withdrawal|withdrawal]],<ref>{{cite journal |author=Pałucha A, Brański P, Pilc A |title=Selective mGlu5 receptor antagonist MTEP attenuates naloxone-induced morphine with-drawal symptoms |journal=Pol J Pharmacol |volume=56 |issue=6 |pages=863–6 |year=2004 |pmid=15662102 |doi= |url=http://www.if-pan.krakow.pl/pjp/pdf/2004/6_863.pdf}}</ref><ref>{{cite journal |author=Rasmussen K, Martin H, Berger JE, Seager MA |title=The mGlu5 receptor antagonists MPEP and MTEP attenuate behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons in rats |journal=Neuropharmacology |volume=48 |issue=2 |pages=173–80 |date=February 2005 |pmid=15695156 |doi=10.1016/j.neuropharm.2004.09.010 |url=}}</ref><ref>{{cite journal |author=Kotlinska J, Bochenski M |title=Comparison of the effects of mGluR1 and mGluR5 antagonists on the expression of behavioral sensitization to the locomotor effect of morphine and the morphine withdrawal jumping in mice |journal=Eur. J. Pharmacol. |volume=558 |issue=1-3 |pages=113–8 |date=March 2007 |pmid=17222405 |doi=10.1016/j.ejphar.2006.11.067 |url=}}</ref> and has anti-addictive effects in a variety of animal models, both reducing ethanol self-administration,<ref>{{cite journal |author=Cowen MS, Djouma E, Lawrence AJ |title=The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems |journal=J. Pharmacol. Exp. Ther. |volume=315 |issue=2 |pages=590–600 |date=November 2005 |pmid=16014750 |doi=10.1124/jpet.105.090449 |url=}}</ref><ref>{{cite journal |author=Cowen MS, Krstew E, Lawrence AJ |title=Assessing appetitive and consummatory phases of ethanol self-administration in C57BL/6J mice under operant conditions: regulation by mGlu5 receptor antagonism |journal=Psychopharmacology (Berl.) |volume=190 |issue=1 |pages=21–9 |date=January 2007 |pmid=17096086 |doi=10.1007/s00213-006-0583-0 |url=}}</ref><ref>{{cite journal |author=Adams CL, Cowen MS, Short JL, Lawrence AJ |title=Combined antagonism of glutamate mGlu5 and adenosine A2A receptors interact to regulate alcohol-seeking in rats |journal=Int. J. Neuropsychopharmacol. |volume=11 |issue=2 |pages=229–41 |date=March 2008 |pmid=17517168 |doi=10.1017/S1461145707007845 |url=}}</ref><ref>{{cite journal |author=Kotlinska J, Bochenski M |title=The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats |journal=Eur. J. Pharmacol. |volume=598 |issue=1-3 |pages=57–63 |date=November 2008 |pmid=18838071 |doi=10.1016/j.ejphar.2008.09.026 |url=}}</ref> and also decreasing the addictive effects of [[nicotine]], [[cocaine]] and [[methamphetamine]].<ref>{{cite journal |author=Dravolina OA, Danysz W, Bespalov AY |title=Effects of group I metabotropic glutamate receptor antagonists on the behavioral sensitization to motor effects of cocaine in rats |journal=Psychopharmacology (Berl.) |volume=187 |issue=4 |pages=397–404 |date=September 2006 |pmid=16896963 |doi=10.1007/s00213-006-0440-1 |url=}}</ref><ref>{{cite journal |author=Palmatier MI, Liu X, Donny EC, Caggiula AR, Sved AF |title=Metabotropic glutamate 5 receptor (mGluR5) antagonists decrease nicotine seeking, but do not affect the reinforcement enhancing effects of nicotine |journal=Neuropsychopharmacology |volume=33 |issue=9 |pages=2139–47 |date=August 2008 |pmid=18046312 |doi=10.1038/sj.npp.1301623 |url= |pmc=2812904}}</ref><ref>{{cite journal |author=Gass JT, Osborne MP, Watson NL, Brown JL, Olive MF |title=mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats |journal=Neuropsychopharmacology |volume=34 |issue=4 |pages=820–33 |date=March 2009 |pmid=18800068 |pmc=2669746 |doi=10.1038/npp.2008.140 |url=}}</ref><ref>{{cite journal |author=Osborne MP, Olive MF |title=A role for mGluR5 receptors in intravenous methamphetamine self-administration |journal=Ann. N. Y. Acad. Sci. |volume=1139 |issue= |pages=206–11 |date=October 2008 |pmid=18991866 |doi=10.1196/annals.1432.034 |url=}}</ref><ref>{{cite journal |author=Martin-Fardon R, Baptista MA, Dayas CV, Weiss F |title=Dissociation of the effects of MTEP [3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]piperidine] on conditioned reinstatement and reinforcement: comparison between cocaine and a conventional reinforcer |journal=J. Pharmacol. Exp. Ther. |volume=329 |issue=3 |pages=1084–90 |date=June 2009 |pmid=19258516 |doi=10.1124/jpet.109.151357 |url= |pmc=2683783}}</ref>
| |||